Details for New Drug Application (NDA): 219713
The generic ingredient in IBTROZI is taletrectinib adipate. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the taletrectinib adipate profile page.
Summary for 219713
| Tradename: | IBTROZI |
| Applicant: | Nuvation |
| Ingredient: | taletrectinib adipate |
| Patents: | 2 |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for 219713
Generic Entry Date for 219713*:
Constraining patent/regulatory exclusivity:
TREATMENT OF ADULT PATIENTS WITH LOCALLY ADVANCED OR METASTATIC ROS1-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC) Dosage:
CAPSULE;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for NDA: 219713
| Mechanism of Action | Proto-Oncogene Tyrosine-Protein Kinase ROS1 Inhibitors |
Suppliers and Packaging for NDA: 219713
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| IBTROZI | taletrectinib adipate | CAPSULE;ORAL | 219713 | NDA | Nuvation Bio Inc. | 84651-200 | 84651-200-90 | 1 BOTTLE in 1 CARTON (84651-200-90) / 90 CAPSULE in 1 BOTTLE |
| IBTROZI | taletrectinib adipate | CAPSULE;ORAL | 219713 | NDA | Nuvation Bio Inc. | 84651-200 | 84651-200-93 | 3 BOTTLE in 1 CARTON (84651-200-93) / 30 CAPSULE in 1 BOTTLE (84651-200-30) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE;ORAL | Strength | EQ 200MG BASE | ||||
| Approval Date: | Jun 11, 2025 | TE: | RLD: | Yes | |||||
| Regulatory Exclusivity Expiration: | Jun 11, 2030 | ||||||||
| Regulatory Exclusivity Use: | NEW CHEMICAL ENTITY | ||||||||
| Regulatory Exclusivity Expiration: | Jun 11, 2032 | ||||||||
| Regulatory Exclusivity Use: | TREATMENT OF ADULT PATIENTS WITH LOCALLY ADVANCED OR METASTATIC ROS1-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC) | ||||||||
| Patent: | ⤷ Start Trial | Patent Expiration: | Jun 3, 2033 | Product Flag? | Y | Substance Flag? | Y | Delist Request? | |
| Patented Use: | TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC ROS1-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC) | ||||||||
Complete Access Available with Subscription
